We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vifor Wins Patent Case Against Teva Over Phosphate-Controlling Velphoro
Vifor Wins Patent Case Against Teva Over Phosphate-Controlling Velphoro
A Delaware federal judge has ruled that a planned generic from Teva Pharmaceuticals infringes on a patent on Vifor Fresenius Medical Care Renal Pharma’s Velphoro (sucroferric oxyhydroxide), a chewable tablet that’s used to control phosphate levels in the blood of chronic kidney disease patients on dialysis.